Ranbaxy Withdraws 27 Approved ANDAs Under Consent Decree

Ranbaxy has withdrawn its approved ANDAs for 27 U.S. drugs to focus on other applications and fixing good manufacturing practice deviations that prompted a consent decree earlier this year. The consent decree specifies that Ranbaxy must never submit another application to the FDA for the withdrawn drug products and must never transfer the ANDAs to a third party. The products are no longer marketed, so the move will have a negligible impact on the company, it said.
Generic Line